Peptides

PT-141 (Bremelanotide): What the Research Actually Shows

A melanocortin-receptor agonist that acts on desire in the brain rather than blood flow in the body, with genuine FDA approval in women and two separate research-integrity problems attached to its evidence base that are worth understanding before using it.

What It Is

A Melanocortin Receptor Agonist, Not a Vascular Drug

Bremelanotide, originally studied under the name PT-141, is a synthetic analog of alpha-melanocyte-stimulating hormone (a-MSH). It works as an agonist at melanocortin receptors, primarily MC4R, expressed in the central nervous system. That mechanism is fundamentally different from the PDE5 inhibitors most people associate with sexual-function drugs (sildenafil, tadalafil), which act peripherally on vascular smooth muscle to increase blood flow. Bremelanotide instead acts on melanocortin signaling pathways in the brain that are implicated in sexual desire and arousal circuits, which is why it is developed and marketed as a treatment for low desire rather than for a purely mechanical erectile or arousal problem.

How Strong Is the Evidence

Evidence Summary

At a Glance
Mechanism confidence Well-characterized as a melanocortin-4 receptor agonist acting centrally, a genuinely different mechanism from peripheral vasodilators, first described in the early 2000s and consistent across two decades of pharmacology work.
Human data FDA-approved (2019, brand name Vyleesi) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), based on two identical randomized, placebo-controlled Phase 3 trials. The effect size was real and statistically significant but modest, and a published 2021 reanalysis found the large majority of the trials' own protocol-specified outcomes were never reported in the original publication.
Specific-condition claims Evidence in men is far thinner than in women. The largest trial ever conducted in men, a 342-patient randomized study, now carries a formal Expression of Concern from the journal that published it, and should not be treated as reliable evidence. What remains for men is two small, early-phase studies from the 2000s.
The Evidence

An FDA Approval in Women, and a Research Record in Men That Has Not Held Up

Mechanism: A Melanocortin Pathway, Mapped Before the Drug Reached Trials

Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. "PT-141: a melanocortin agonist for the treatment of sexual dysfunction." Annals of the New York Academy of Sciences. 2003;994:96-102. PMID: 12851303. This early paper, published under the compound's original research name PT-141, laid out the melanocortin mechanism and reported that administration to normal men and to men with erectile dysfunction produced a rapid, dose-dependent erectile response, distinct from the vascular mechanism of PDE5 inhibitors. It is mechanism and early pharmacodynamic work, not a large controlled outcome trial.

Early Pharmacology and Small Open-Label Dosing Work, Early 2000s · Endpoint: Mechanism and Dose-Response, Not a Randomized Outcome Trial

A Small Combination Study in Men With Erectile Dysfunction

Diamond LE, Earle DC, Garcia WD, Spana C. "Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response." Urology. 2005;65(4):755-759. doi: 10.1016/j.urology.2004.10.060. PMID: 15833522. In this small trial of 19 men with erectile dysfunction, subtherapeutic doses of PT-141 combined with subtherapeutic doses of sildenafil produced a stronger erectile response than either subtherapeutic dose alone, supporting the idea of two distinct, additive mechanisms (central desire/arousal signaling plus peripheral vasodilation). The sample size is too small to establish efficacy on its own.

Human Pilot Study (n=19) · Endpoint: Erectile Response to Combination Dosing, Small Sample, Hypothesis-Generating

FDA Approval in Women: The RECONNECT Phase 3 Trials

Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. "Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials." Obstetrics & Gynecology. 2019;134(5):899-908. doi: 10.1097/AOG.0000000000003500. PMID: 31599840. These two identical, randomized, double-blind, placebo-controlled trials in premenopausal women with acquired, generalized HSDD form the basis of bremelanotide's 2019 FDA approval as Vyleesi, the second approved medication for this condition. Both trials found statistically significant improvement in desire and a significant decrease in HSDD-related distress with active drug over placebo. Simon JA, Kingsberg SA, Portman D, et al. "Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder." Obstetrics & Gynecology. 2019;134(5):909-917. doi: 10.1097/AOG.0000000000003514. PMID: 31599847. This open-label extension of the same program found the safety and effect profile held up over roughly a year of continued use. The most common adverse effects across the program were nausea (about 40% of patients), facial flushing (about 20%), and headache (about 11%), and a separate pharmacology review (Mayer D, Lynch SE. Annals of Pharmacotherapy. 2020;54(7):684-690. PMID: 31893927) characterizes the clinical benefit, while statistically real, as likely modest.

Two Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials Plus Open-Label Extension · Endpoint: HSDD Desire and Distress Scores, Basis of FDA Approval

A Published Reanalysis Raises Questions About What Wasn't Reported

Spielmans GI. "Re-Analyzing Phase III Bremelanotide Trials for 'Hypoactive Sexual Desire Disorder' in Women." Journal of Sex Research. 2021;58(9):1085-1105. doi: 10.1080/00224499.2021.1885601. PMID: 33678061. This independent reanalysis compared the trials' published results against their original registered protocols and found that roughly 73% of the protocol-listed outcome measures from the RECONNECT trials were never reported in the published paper. Selective outcome reporting of this scale does not mean the drug doesn't work, but it does mean the full picture of how well it worked, across every measure the trial was actually designed to capture, is not available in the literature that supported approval.

Independent Methodological Reanalysis, 2021 · Endpoint: Comparison of Registered Protocol Outcomes vs. Published Outcomes, Not a New Clinical Trial

The Largest Trial in Men Now Carries a Formal Expression of Concern

Safarinejad MR, Hosseini SY. "Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study." Journal of Urology. 2008;179(3):1066-1071. PMID: 18206919. As originally published, this was the largest bremelanotide trial ever conducted in men: 342 men with erectile dysfunction who had not responded to sildenafil, randomized to intranasal bremelanotide or placebo, reporting a positive response in 33.5% of the bremelanotide group versus 8.5% of the placebo group. In January 2023, the Journal of Urology published a formal Expression of Concern on this paper (PMID: 36626345), a step journals take when a study's data or conduct is under unresolved investigation, short of a full retraction. This is one of several papers by the same lead author to receive this designation. Until and unless that concern is resolved, this trial should not be treated as reliable evidence, which leaves the small pilot studies above as the actual evidence base for bremelanotide in men.

Formerly the Largest Human RCT in Men (n=342), Now Under Formal Expression of Concern (2023) · Endpoint: Erectile Response After Sildenafil Failure, Reliability Currently Unresolved
Honest Limits

What the Research Doesn't Yet Show

Bremelanotide is not FDA-approved for men, or for postmenopausal women, or for any use outside premenopausal HSDD. There is no meaningful Phase 3-scale trial of it in men that is not currently under a formal Expression of Concern, which means claims about its effectiveness for male sexual function rest on studies of fewer than 20 patients. Even in the population where it is approved, the clinical benefit is described by independent pharmacology reviewers as real but modest, and a substantial share of the original trials' planned outcome measures were never published. Common side effects, nausea, facial flushing, and a transient rise in blood pressure, are frequent enough to affect a meaningful minority of users.

FDA-approved as Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder; not FDA-approved for any other population or indication, including use in men. The compounded bremelanotide prescribed in this practice has not itself undergone FDA review.

Where This Fits

How This Fits the Cellular Medicine Framework

Bremelanotide is a cell-signaling intervention in the truest sense used on this site: it engages a specific G-protein-coupled receptor (MC4R) in the central nervous system to change downstream neural circuitry governing desire and arousal, rather than acting on blood vessels, muscle, or a peripheral organ directly. That makes it a useful illustration that this framework isn't only about metabolic or hormonal signaling, the same signal-to-symptom logic applies to neuroendocrine and behavioral pathways. It's also a useful case study in why mechanism confidence and clinical-evidence confidence have to be scored separately: the receptor biology here is solid, but two independent integrity questions, one about a reanalysis of what was reported in the pivotal female trials and one a formal concern about the largest male trial, mean the clinical evidence has to be read more cautiously than the mechanism alone would suggest.

See the Full Framework
Sources

References

Cited on This Page
  1. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102. PMID: 12851303
  2. Diamond LE, Earle DC, Garcia WD, Spana C. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology. 2005;65(4):755-759. PMID: 15833522
  3. Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. PMID: 31599840
  4. Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Clayton AH. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019;134(5):909-917. PMID: 31599847
  5. Mayer D, Lynch SE. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. Ann Pharmacother. 2020;54(7):684-690. PMID: 31893927
  6. Spielmans GI. Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women. J Sex Res. 2021;58(9):1085-1105. PMID: 33678061
  7. Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol. 2008;179(3):1066-1071. PMID: 18206919 · Expression of Concern, PMID: 36626345
See the Framework Applied

Explore the Rest of the Knowledge Center

Hormones, Women's Health, Men's Health, Peptides, and Metabolic Health, five practical categories, one shared framework underneath all of them.

Explore the Knowledge Center